AZN
AstraZeneca PLC · Healthcare
202.83
0.32%(-0.66)
Prev. Close202.50
0.16%(-0.33)
Pre-marketLast Updated: — ET
52W L: $122.4852W H: $212.71
$199.67
CHG-175.83 (-46.83%)
H$403.06
L$178.81
VOL27M
AZN (1h)
AstraZeneca PLC · Healthcare
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers. Liver cancer is one...
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers. Liver cancer is one of the most difficult cancers to treat, and for patients whose tumours cannot be surgically removed, options have historically been limited.
Perpetual Ltd decreased its position in shares of Astrazeneca Plc (NYSE: AZN) by 60.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,606 shares of the company's stock after selling 8,513 shares during the quarter. Perpetual
Aspiriant LLC purchased a new position in Astrazeneca Plc (NYSE: AZN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,567 shares of the company's stock, valued at approximately $236,000. Other institutional investors have also added to or reduced their stakes
AstraZeneca remains a long-term buy, driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched. AZN's 2025 results showed 8% revenue and 11% EPS growth, with oncology (44% of revenue) and rare diseases as key growth engines. Patent expirations for Farxiga and price pressures in China pose near-term headwinds, but pipeline innovation and emerging market growth underpin future prospects.
Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior day's close.
Sharma Mani
officer: See Remarks
0 SH @ $0.00
2026-03-18
Sharma Mani
officer: See Remarks
2,996.308 SH @ $0.00
2026-03-18
Sharma Mani
officer: See Remarks
31.297 SH @ $0.00
2026-03-18
Sharma Mani
officer: See Remarks
195 SH @ $123.98
2028-12-01